Here are three things to know:
1. SpinalCyte is a tissue engineering technology company focused on developing an innovative and autologous solution for spinal nucleus replacement using human dermal fibroblasts.
2. Howard An, MD, director, division of spine surgery and spine fellowship program at Rush University Medical Center in Chicago is the principal investigator of the studies, which began in 2014.
3. Dr. An’s team is reporting a significant increase in disc height indexes in the discs treated with human dermal fibroblasts.
More articles on devices:
InVivo continues to see success with INSPIRE study—5 observations
Stryker gears up its challenge at first stop on PGA Tour: 3 notes
Amedica, Stryker, SI-BONE & & more: 12 key notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
